Funding for this research was provided by:
F. Hoffmann-La Roche
Received: 5 July 2018
Accepted: 4 September 2018
First Online: 24 September 2018
Ethics approval and consent to participate
: This study was conducted in full conformance with the ICH E6 Guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. It was approved by the institutional review boards or ethics committees of the study sites.
: Not applicable.
: GH, CH, MT, and ND are employees of F. Hoffman-La Roche Ltd., and ND holds stock in F. Hoffman-La Roche Ltd. VM is an employee of Roche-Genentech, Ltd. SK reports receiving honoraria for advisory board participation, travel expenses, and research funding by Novartis, in addition to the funding of this study by F. Hoffmann-LaRoche Ltd. JC, SC, GB, WD, SV, and FP declare that they have no competing interests other than the funding of this study by F. Hoffmann-LaRoche Ltd.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.